The neuropharmacologic mechanisms underlying
neuroleptic-induced extrapyramidal syndromes (EPS) were studied using a nonhuman primate model. Twenty-six Cebus albifrons monkeys were given weekly challenges of
haloperidol (0.025 mg/kg IM), and half of the animals received the
monoamine oxidase (
MAO) inhibitor pargyline (5 mg/kg PO) daily for 17 consecutive days during the protocol.
Pargyline caused no changes in baseline behaviors, but significantly
reduced haloperidol-induced acute
dystonia (AD) (-67%, P less than 0.002) and
parkinsonism (-56%, P less than 0.005). The majority (8 of 13) of the experimental group had complete prevention of
neuroleptic-induced EPS during cotreatment with
pargyline. Behavioral scores returned to baseline levels after stopping
pargyline, and did not show the further sensitization to
haloperidol-induced AD that occurred in the control group. The possible mechanisms by which an
MAO inhibitor might influence
neuroleptic-induced AD were considered. The most likely explanation would appear to involve facilitation of striatal
dopamine (DA) neurotransmission by inhibition of intra- and extraneuronal
MAO, thus supporting the hypothesis that AD is due to decreased striatal DA function with secondary
cholinergic hyperfunction.